3rd Quarter - Report

NOVOCURE INC. for NOVOCURE INC.

Firm
Client
Income
—
Expenses
$160,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

General Medicare Issues. H.R.5343/S.1717 - Ensuring Patient Access to Critical Breakthrough Products Act of 2025.

Foreign entity interest: Novocure GmbH, Novocure Luxembourg S.a.r.l. (who owns 100% of Novocure GmbH) and NovoCure Limited (who owns 100% of Luxembourg S.a.r.l.), identified on filer's Registration Statement (LD-1), as its parent organization, has an interest in the listed issues.

LobbyistCovered position, as disclosed
KATHERINE MEYER Senior Policy Advisor, Office of House Republican Leader Kevin McCarthy; Deputy Health Policy Director, Senate Finance Committee; Health Policy Advisor, Senator Orrin Hatch; Sr. LA, Congressman Erik Paulsen; LA, Congressman Jeff Fortenberry
ELLE WHITSON Covered Official Positions Continued: Health Policy Advisor, Congresswoman Cathy McMorris Rogers; Staff Assistant / Legislative Correspondent / Legislative Assistant, Congressman Ryan Costello

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS)

Bills named: H.R. 5343 (119th), S. 1717 (119th)

Tariff (miscellaneous tariff bills) TAR

Tariff issues, specifically related to medical device 232.

Foreign entity interest: Novocure GmbH, Novocure Luxembourg S.a.r.l. (who owns 100% of Novocure GmbH) and NovoCure Limited (who owns 100% of Luxembourg S.a.r.l.), identified on filer's Registration Statement (LD-1), as its parent organization, has an interest in the listed issues.

LobbyistCovered position, as disclosed
KATHERINE MEYER —
ELLE WHITSON —

Contacted: Commerce, Dept of (DOC); U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.